Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H38F2N4O3 |
Molecular Weight | 576.6766 |
Optical Activity | ( + ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)NC1(CCN(CC[C@]2(CN(CCO2)C(=O)C3=CC=CC=C3)C4=CC(F)=C(F)C=C4)CC1)C5=CC=CC=C5
InChI
InChIKey=QNLIUVLFRVYNCV-XIFFEERXSA-N
InChI=1S/C33H38F2N4O3/c1-37(2)31(41)36-32(26-11-7-4-8-12-26)15-18-38(19-16-32)20-17-33(27-13-14-28(34)29(35)23-27)24-39(21-22-42-33)30(40)25-9-5-3-6-10-25/h3-14,23H,15-22,24H2,1-2H3,(H,36,41)/t33-/m0/s1
Molecular Formula | C33H38F2N4O3 |
Molecular Weight | 576.6766 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:42:24 GMT 2023
by
admin
on
Sat Dec 16 09:42:24 GMT 2023
|
Record UNII |
Y2646FAP82
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9916195
Created by
admin on Sat Dec 16 09:42:24 GMT 2023 , Edited by admin on Sat Dec 16 09:42:24 GMT 2023
|
PRIMARY | |||
|
201152-86-5
Created by
admin on Sat Dec 16 09:42:24 GMT 2023 , Edited by admin on Sat Dec 16 09:42:24 GMT 2023
|
PRIMARY | |||
|
Y2646FAP82
Created by
admin on Sat Dec 16 09:42:24 GMT 2023 , Edited by admin on Sat Dec 16 09:42:24 GMT 2023
|
PRIMARY | |||
|
DTXSID3047340
Created by
admin on Sat Dec 16 09:42:24 GMT 2023 , Edited by admin on Sat Dec 16 09:42:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
SR 144190 potently and selectively inhibited neurokinin A binding to NK2 receptors from various species, including humans. In in vitro functional assays, it was a potent, selective and competitive antagonist of NK2 receptors with apparent affinities (pA2 values) between 9.08 and 10.10. In vivo, SR 144190 blocked [Nle10]neurokinin A-(4-10)-induced bronchoconstriction in guinea pigs (ID50 = 21 micrograms kg-1 i.v. and 250 micrograms kg-1 i.d.) and [beta Ala8]neurokinin A-(4-10)-induced urinary bladder contraction in rats (ID50 = 11 micrograms kg-1 i.v. and 190 micrograms kg-1 i.d.).
|